目的 探讨甲磺酸倍他司汀联合缬沙坦治疗老年高血压性眩晕的效果及安全性。方法 选取2022年1月—2023年12月在常州市肿瘤医院就诊的68例老年高血压性眩晕患者为研究对象。采用随机数字表法分为对照组与观察组，各34例。对照组采用缬沙坦控制血压水平，观察组在此基础上加用甲磺酸倍他司汀。对比2组临床疗效、欧洲眩晕评价量表(the European evaluation of vertigo scale，EEV)评分、收缩压、舒张压、脑血流速度、内皮素-1(endothelin-1，ET-1)及药物使用安全性。结果 观察组治疗总有效率为91。18％，高于对照组的67。65％，差异有统计学意义(P<0。05)。治疗后，观察组EEV评分、收缩压、舒张压分别为(5。60±1。28)分、(127。55±15。30)mmHg、(71。81±6。37)mmHg，均低于对照组的(8。11±2。00)分、(137。46±20。04)mmHg、(76。12±5。46)mmHg，差异有统计学意义(P<0。05)。治疗后，观察组右椎动脉平均血流速度(mean blood flow velocity，Vm)、左椎动脉Vm、基底动脉Vm分别为(46。87±6。77)cm/s、(47。94±7。11)cm/s、(48。52±5。50)cm/s，高于对照组的(41。58±5。22)cm/s、(42。18±6。31)cm/s、(43。87±6。02)cm/s;观察组ET-1水平为(110。10±19。89)ng/L，低于对照组的(143。67±24。01)ng/L，差异有统计学意义(P<0。05)。2组均未发生明显的药物不良反应。结论 甲磺酸倍他司汀联合缬沙坦治疗老年高血压性眩晕的疗效显著，并能促进血压、脑血流速度、血管内皮功能的改善，用药安全可靠。
Effect of Betahistine Mesylate Combined With Valsartan in the Treatment of Elderly Patients With Hypertensive Vertigo
Objective To investigate the efficacy and safety of betahistine mesylate combined with valsartan in the treatment of elderly patients with hypertensive vertigo. Methods A total of 68 elderly patients with hypertensive vertigo treated in Changzhou Cancer Hospital from January 2022 to December 2023 were selected as the study objects. They were divided into control group and observation group by random number table method,34 cases in each group. The control group was treated with valsartan to control blood pressure level,and the observation group was treated with betastatin mesylate on this basis. The clinical effects,the score of the European evaluation of vertigo scale (EEV),systolic blood pressure,diastolic blood pressure,cerebral blood flow velocity,endothelin-1 (ET-1) and drug safety were compared between the two group. Results The total effective rate of the observation group was 91.18％,which was higher than 67.65％ of the control group,and the difference was statistically significant (P<0.05). After treatment,EEV score,systolic blood pressure and diastolic blood pressure in the observation group were (5.60±1.28) points,(127.55±15.30) mmHg and (71.81±6.37) mmHg,which were lower than (8.11±2.00) points,(137.46±20.04) mmHg,(76.12±5.46) mmHg in the control group,and the differences were statistically significant (P<0.05). After treatment,the mean blood flow velocity (Vm) of right vertebral artery,Vm of left vertebral artery and Vm of basilar artery in the observation group were (46.87±6.77) cm/s,(47.94±7.11) cm/s and (48.52±5.50) cm/s,respectively,which were higher than (41.58±5.22) cm/s,(42.18±6.31) cm/s,(43.87±6.02) cm/s in the control group,the ET-1 level in the observation group was (110.10±19.89) ng/L,which was lower than (143.67±24.01) ng/L in the control group,and the differences were statistically significant (P<0.05). No obvious adverse drug reaction occurred in both groups. Conclusion Betahistine mesylate combined with valsartan is effective in the treatment of elderly hypertensive vertigo,and can promote the improvement of blood pressure,cerebral blood flow velocity and vascular endothelial function,and the drug is safe and reliable.
万方数据
维普
